From Remdesivir to Human Convalescent Plasma - Understanding COVID-19 Therapeutic Development

Explore the early therapeutic approaches to COVID-19 in this 57-minute webinar from the American Society for Microbiology. Delve into the promising treatments of human convalescent plasma (HCP) and antiviral drugs like Remdesivir. Hear opening remarks from Senator Bob Casey and gain insights from expert panelists Dr. Arturo Casadevall and Dr. Mark Denison. Learn about the National Convalescent Plasma Project, its goals, and biological foundations. Discover how historical events, like the use of boys' blood to stop an outbreak, influenced current strategies. Examine the global efforts in China, Italy, and the United States, including FDA partnerships and clinical trials. Gain understanding of the efficacy, hopeful signs, and future horizons for COVID-19 therapeutics. Conclude with a Q&A session to address remaining questions about these cutting-edge treatment approaches.

Introduction
Opening Remarks
Dr Patel
Dr Dennison
Grant Application
Goals
Biology
Conclusion
Convalescent Plasma
Summary
Wuhan 2019
How Boys Blood Stopped the Outbreak
The National Convalescent Plasma Project
Covid Time
FDA Partners
Number of Sites
Publications
China
Italy
United States
Hopeful Signs
Efficacy
Clinical Trials
Near and Far Horizon
QA